Premium
Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation
Author(s) -
Isaias Ioannis U.,
Benti Riccardo,
Goldwurm Stefano,
Zini Michela,
Cilia Roberto,
Gerundini Paolo,
Di Fonzo Alessio,
Bonifati Vincenzo,
Pezzoli Gianni,
Antonini Angelo
Publication year - 2006
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20909
Subject(s) - putamen , dopamine transporter , caudate nucleus , lrrk2 , dopaminergic , parkinson's disease , medicine , degenerative disease , central nervous system disease , psychology , endocrinology , dopamine , gastroenterology , disease
We measured striatal dopamine transporter binding using [ 123 I]ioflupane and SPECT in patients with Parkinson's disease associated with the LRRK2 (PARK8) Gly2019Ser gene mutation (LRRK2‐PD) and in gene‐negative patients with idiopathic Parkinson's disease (IPD) of comparable disease duration and severity. The LRRK2‐PD group consisted of a total of 10 patients (3 sporadic) with mean age 62 ± 14 years, disease duration 9 ± 3 years, and UPDRS III motor score 21.60 ± 6.65. The control IPD group consisted of 15 patients with mean age 59 ± 9 years, disease duration 9 ± 5 years, and UPDRS III motor score 23.80 ± 8.69. [ 123 I]ioflupane–specific uptake ratios were calculated for caudate nucleus and putamen using the occipital cortex as reference region. We found no differences between the LRRK2‐PD group and IPD in all items studied. In particular, putamen and caudate uptake values as well as side asymmetry indexes and putamen/caudate ratios all revealed comparable between‐group values. We conclude that in these patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD. © 2006 Movement Disorder Society